You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,354,654


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,354,654
Title: Lyophilized ligand-receptor complexes for assays and sensors
Abstract:A dry reagent prepared by lyophilizing a labelled ligand-immobilized receptor complex or a labelled receptor-immobilized ligand complex is, on rehydration, useful for detecting analytes in samples in a variety of displacement assays.
Inventor(s): Ligler; Frances S. (Potomac, MD), Whelan; James P. (Potomac, MD)
Assignee: The United States of America as Represented by the Secretary of the Navy (Washington, DC) U.S. Drug Testing, Inc. (Rancho Cucamonga, CA)
Application Number:08/092,518
Patent Claims:1. A lyophilized ligand-receptor complex, prepared by a process comprising:

(i) binding a labelled ligand or a labelled receptor to an immobilized receptor or an immobilized ligand, to obtain an immobilized ligand-receptor complex;

(ii) washing said immobilized ligand-receptor complex to remove any excess labelled ligand or any excess labelled receptor, to obtain a washed immobilized ligand-receptor complex; and

(iii) lyophilizing said washed immobilized ligand-receptor complex, to obtain a lyophilized immobilized ligand-receptor complex,

wherein said lyophilizing is carried out .in the presence of a cryoprotectant.

2. The lyophilized ligand-receptor complex of claim 1, wherein step (i) is carried out by binding a labelled antigen or labelled hapten to an immobilized antibody and wherein said lyophilized immobilized ligand-receptor complex is a lyophilized labelled antigen-immobilized antibody complex or a lyophilized labelled hapten-immobilized antibody complex.

3. The lyophilized ligand-receptor complex of claim 1, wherein said cryoprotectant is selected from the group consisting of disaccharides, polysaccharides, glycerol, proteins, surfactants, serum, buffers, polyethylene glycol, and dimethyl sulfoxide.

4. The lyophilized ligand-receptor complex of claim 1, wherein said immobilized receptor or immobilized ligand is capable of specific binding to an analyte selected from the group consisting of acetylcholine receptor antibody, adenovirus antigens, antibodies against adenovirus, aldosterone, acid phosphatase, alpha-1 fetoprotein, angiotensin converting enzyme, antiDNA antibody, antimitochondrial antibody, beta-2 microglobulin, creatine kinase isoenzymes, lactate dehydrogenase isoenzymes, complement components, chlamydia antigens, antibodies against chlamydia, cortisol, C-peptide, cyclic AMP, erthyropoietin, estradiol, ferritin, folic acid, follicle stimulating hormone, gastrin, glucagon, growth hormone, histocompatibility antigens, blood group antigens A and B, haptoglobin, antibodies against hepatitis A and B, hepatitis A and B antigens, antibodies against herpes, herpes antigens, human chorionic gonadotropin, HIV antigens, antibodies against HIV, antibodies against insulin, insulin, IgA, IgD, IgE, IgG, IgM, H. influenza antigen, antibodies against the H. influenza virus, intrinsic factor antibody, Borrelia burgdorferi antigens, antibodies against Borrelia burgdoferi, luteinizing hormone, metyrapone, myoglobin, neuron-specific-enolase, p24, pancreatic polypeptide, parathyroid hormone, placental lactogen, progesterone, prolactin, prostate specific antigen, rotavirus antigens, antibodies against rotavirus, antibodies against rubella, salmonella, serotonin, somatomedin-C, T.sub.3, T.sub.4, testosterone, thyroglobulin, thyroid stimulating hormone, thyroxine, thyroxine binding globulin, transferrin, tri-iodothyronine, vasoactive intestinal polypeptide, vitamins B.sub.6 and B.sub.12, staphylococcus antigens, antibodies against staphylococcus, enterotoxins, ricin, endotoxin, botulism toxin, venoms, amphetamine, methamphetamine, phenobarbital, cocaine, methadone, methaqualone, opiates (morphine, heroin), tetrahydrocannabinol (THC), phencyclidine (PCP), lysergic acid diethylamide (LSD), annabolic steroids, phenyl-butazone, amikacin, azidothymidine, benzodiazepines (diazepam and chlordiazepoxide), carbamazine, chloramphenicol, cyclosporine, digitoxin, digoxin, ethosuximide, gentamicin, imipramine, lidocaine, phenytoin, primidone, procainamide, propoxyphene, propranolol, quinidine, theophylline, tobramycin, valproic acid, trinitrotoluene, cyclonite, pentaerythritol tetranitrate, picric acid, nitroglycerin, herbicides, insecticides, polychlorinated biphenyls, polyaromatic hydrocarbons, heavy metals, glucose, F1 antigen of Y pestis, lethal factor or PA antigen from B. anthracis, and mycotoxins.

5. A process for preparing a lyophilized ligand-receptor complex, comprising:

(i) binding a labelled ligand or a labelled receptor to an immobilized receptor or an immobilized ligand, to obtain an immobilized ligand-receptor complex;

(ii) washing said immobilized ligand-receptor complex to remove any excess labelled ligand or any excess labelled receptor, to obtain a washed immobilized ligand-receptor complex; and

(iii) lyophilizing said washed immobilized ligand-receptor complex, to obtain a lyophilized immobilized ligand-receptor complex,

wherein said lyophilizing is carried out in the presence of a cryoprotectant.

6. The process of claim 5, wherein step (i) is carried out by binding a labelled antigen or labelled hapten to an immobilized antibody and wherein said lyophilized immobilized ligand-receptor complex is a lyophilized labelled antigen-immobilized antibody complex or a lyophilized labelled hapten-immobilized antibody complex.

7. The process of claim 5, wherein said cryoprotectant is selected from the group consisting of disaccharides, polysaccharides, glycerol, proteins, surfactants, serum, buffers, polyethylene glycol, and dimethyl sulfoxide.

8. The process of claim 5, wherein said immobilized receptor or immobilized ligand is capable of specific binding to an analyte selected from the group consisting of acetylcholine receptor antibody, adenovirus antigens, antibodies against adenovirus, aldosterone, acid phosphatase, alpha-1 fetoprotein, angiotensin converting enzyme, antiDNA antibody, antimitochondrial antibody, beta-2 microglobulin, creatine kinase isoenzymes, lactate dehydrogenase isoenzymes, complement components, chlamydia antigens, antibodies against chlamydia, cortisol, C-peptide, cyclic AMP, erthyropoietin, estradiol, ferritin, folic acid, follicle stimulating hormone, gastrin, glucagon, growth hormone, histocompatibility antigens, blood group antigens A and B, haptoglobin, antibodies against hepatitis A and B, hepatitis A and B antigens, antibodies against herpes, herpes antigens, human chorionic gonadotropin, HIV antigens, antibodies against HIV, antibodies against insulin, insulin, IgA, IgD, IgE, IgG, IgM, H. influenza antigen, antibodies against the H. influenza virus, intrinsic factor antibody, Borrelia burgdorferi antigens, antibodies against Borrelia burgdoferi, luteinizing hormone, metyrapone, myoglobin, neuron-specific-enolase, p24, pancreatic polypeptide, parathyroid hormone, placental lactogen, progesterone, prolactin, prostate specific antigen, rotavirus antigens, antibodies against rotavirus, antibodies against rubella, salmonella, serotonin, somatomedin-C, T.sub.3, T.sub.4, testosterone, thyroglobulin, thyroid stimulating hormone, thyroxine, thyroxine binding globulin, transferrin, tri-iodothyronine, vasoactive intestinal polypeptide, vitamins B.sub.6 and B.sub.12, staphylococcus antigens, antibodies against staphylococcus, enterotoxins, ricin, endotoxin, botulism toxin, venoms, amphetamine, methamphetamine, phenobarbital, cocaine, methadone, methaqualone, opiates (morphine, heroin), tetrahydrocannabinol (THC), phencyclidine (PCP), lysergic acid diethylamide (LSD), annabolic steroids, phenyl-butazone, amikacin, azidothymidine, benzodiazepines (diazepam and chlordiazepoxide), carbamazine, chloramphenicol, cyclosporine, digitoxin, digoxin, ethosuximide, gentamicin, imipramine, lidocaine, phenytoin, primidone, procainamide, propoxyphene, propranolol, quinidine, theophylline, tobramycin, valproic acid, trinitrotoluene, cyclonite, pentaerythritol tetranitrate, picric acid, nitroglycerin, herbicides, insecticides, polychlorinated biphenyls, polyaromatic hydrocarbons, heavy metals, glucose, F1 antigen of Y pestis, lethal factor or PA-antigen from B. anthracis, and mycotoxins.

9. A lyophilized, dry reagent, comprising: (a) a labeled ligand or labeled receptor bound to (b) a complementary receptor or a complementary ligand, wherein said complementary receptor or complementary ligand is immobilized on a solid support, wherein said lyophilized, dry reagent is prepared by lyophilizing in the presence of a cryoprotectant.

10. The dry reagent of claim 9, comprising a labelled antigen or labelled hapten bound to a complementary antibody, wherein said complementary antibody is immobilized on a solid support.

11. The lyophilized, dry reagent of claim 9, wherein said immobilized receptor or immobilized ligand is capable of specific binding to an analyte selected from the group consisting of acetylcholine receptor antibody, adenovirus antigens, antibodies against adenovirus, aldosterone, acid phosphatase, alpha-1 fetoprotein, angiotensin converting enzyme, antiDNA antibody, antimitochondrial antibody, beta-2 microglobulin, creatine kinase isoenzymes, lactate dehydrogenase isoenzymes, complement components, chlamydia antigens, antibodies against chlamydia, cortisol, C-peptide, cyclic AMP, erthyropoietin, estradiol, ferritin, folic acid, follicle stimulating hormone, gastrin, glucagon, growth hormone, histocompatibility antigens, blood group antigens A and B, haptoglobin, antibodies against hepatitis A and B, hepatitis A and B antigens, antibodies against herpes, herpes antigens, human chorionic gonadotropin, HIV antigens, antibodies against HIV, antibodies against insulin, insulin, IgA, IgD, IgE, IgG, IgM, H. influenza antigen, antibodies against the H. influenza virus, intrinsic factor antibody, Borrelia burgdorferi antigens, antibodies against Borrelia burgdoferi, luteinizing hormone, metyrapone, myoglobin, neuron-specific-enolase, p24, pancreatic polypeptide, parathyroid hormone, placental lactogen, progesterone, prolactin, prostate specific antigen, rotavirus antigens, antibodies against rotavirus, antibodies against rubella, salmonella, serotonin, somatomedin-C, T.sub.3, T.sub.4, testosterone, thyroglobulin, thyroid stimulating hormone, thyroxine, thyroxine binding globulin, transferrin, tri-iodothyronine, vasoactive intestinal polypeptide, vitamins B.sub.6 and B.sub.12, staphylococcus antigens, antibodies against staphylococcus, enterotoxins, ricin, endotoxin, botulism toxin, venoms, amphetamine, methamphetamine, phenobarbital, cocaine, methadone, methaqualone, opiates (morphine, heroin), tetrahydrocannabinol (THC), phencyclidine (PCP), lysergic acid diethylamide (LSD), annabolic steroids, phenyl-butazone, amikacin, azidothymidine, benzodiazepines (diazepam and chlordiazepoxide), carbamazine, chloramphenicol, cyclosporine, digitoxin, digoxin, ethosuximide, gentamicin, imipramine, lidocaine, phenytoin, primidone, procainamide, propoxyphene, propranolol, quinidine, theophylline, tobramycin, valproic acid, trinitrotoluene, cyclonite, pentaerythritol tetranitrate, picric acid, nitroglycerin, herbicides, insecticides, polychlorinated biphenyls, polyaromatic hydrocarbons, heavy metals, glucose, F1 antigen of Y pestis, lethal factor or PA antigen from B. anthracis, and mycotoxins.

12. A displacement assay for detecting an analyte in a sample, comprising:

(a) contacting a sample which may contain said analyte with an immobilized ligand-receptor complex prepared by a process comprising:

(i) binding a labelled ligand or a labelled receptor to an immobilized receptor or an immobilized ligand, to obtain an immobilized ligand-receptor complex;

(ii) washing said immobilized ligand-receptor complex to remove any excess labelled ligand or any excess labelled receptor, to obtain a washed immobilized ligand-receptor complex;

(iii) lyophilizing said washed immobilized ligand-receptor complex, to obtain a lyophilized immobilized ligand-receptor complex, wherein said lyophilizing is carried out in the presence of a cryoprotectant; and

(iv) rehydrating said lyophilized immobilized ligand-receptor complex; and

(b) measuring (1) the amount of labelled ligand or labelled receptor displaced from said immobilized receptor or said immobilized ligand, or (2) the amount of labelled ligand or labelled receptor which remains bound to said immobilized receptor or said immobilized ligand.

13. The displacement assay of claim 12, wherein step (i) is carried out by binding a labelled antigen or labelled hapten to an immobilized antibody and wherein said lyophilized immobilized ligand-receptor complex is a lyophilized labelled antigen-immobilized antibody complex or a lyophilized labelled hapten-immobilized antibody complex.

14. The displacement assay claim 12, wherein said cryoprotectant is selected from the group consisting of disaccharides, polysaccharides, glycerol, proteins, surfactants, serum, buffers, polyethylene glycol, and dimethyl sulfoxide.

15. The displacement assay of claim 12, wherein said immobilized receptor or immobilized ligand is capable of specific binding to an analyte selected from the group consisting of acetylcholine receptor antibody, adenovirus antigens, antibodies against adenovirus, aldosterone, acid phosphatase, alpha-1 fetoprotein, angiotensin converting enzyme, antiDNA antibody, antimitochondrial antibody, beta-2 microglobulin, creatine kinase isoenzymes, lactate dehydrogenase isoenzymes, complement components, chlamydia antigens, antibodies against chlamydia, cortisol, C-peptide, cyclic AMP, erthyropoietin, estradiol, ferritin, folic acid, follicle stimulating hormone, gastrin, glucagon, growth hormone, histocompatibility antigens, blood group antigens A and B, haptoglobin, antibodies against hepatitis A and B, hepatitis A and B antigens, antibodies against herpes, herpes antigens, human chorionic gonadotropin, HIV antigens, antibodies against HIV, antibodies against insulin, insulin, IgA, IgD, IgE, IgG, IgM, H. influenza antigen, antibodies against the H. influenza virus, intrinsic factor antibody, Borrelia burgdorferi antigens, antibodies against Borrelia burgdoferi, luteinizing hormone, metyrapone, myoglobin, neuron-specific-enolase, p24, pancreatic polypeptide, parathyroid hormone, placental lactogen, progesterone, prolactin, prostate specific antigen, rotavirus antigens, antibodies against rotavirus, antibodies against rubella, salmonella, serotonin, somatomedin-C, T.sub.3, T.sub.4, testosterone, thyroglobulin, thyroid stimulating hormone, thyroxine, thyroxine binding globulin, transferrin, tri-iodothyronine, vasoactive intestinal polypeptide, vitamins B.sub.6 and B.sub.12, staphylococcus antigens, antibodies against staphylococcus, enterotoxins, ricin, endotoxin, botulism toxin, venoms, amphetamine, methamphetamine, phenobarbital, cocaine, methadone, methaqualone, opiates (morphine, heroin), tetrahydrocannabinol (THC), phencyclidine (PCP), lysergic acid diethylamide (LSD), annabolic steroids, phenyl-butazone, amikacin, azidothymidine, benzodiazepines (diazepam and chlordiazepoxide ), carbamazine, chloramphenicol, cyclosporine, digitoxin, digoxin, ethosuximide, gentamicin, imipramine, lidocaine, phenytoin, primidone, procainamide, propoxyphene, propranolol, quinidine, theophylline, tobramycin, valproic acid, trinitrotoluene, cyclonite, pentaerythritol tetranitrate, picric acid, nitroglycerin, herbicides, insecticides, polychlorinated biphenyls, polyaromatic hydrocarbons, heavy metals, glucose, F1 antigen of Y pestis, lethal factor or PA antigen from B. anthracis, and mycotoxins.

16. The displacement assay of claim 12, wherein said contacting comprises flowing said sample past said immobilized ligand-receptor complex at a flow rate allowing said analyte to displace said labelled ligand or said labelled receptor from said ligand-receptor complex under nonequilibrium conditions.

17. The displacement assay of claim 16, wherein said flowing of said sample past said immobilized ligand-receptor complex is carried out in a column.

18. The displacement assay of claim 16, wherein said flowing of said sample past said ligand-receptor complex is carried out at a flow rate between 0.1 and 2.0 milliliters per minute.

19. The displacement assay of claim 16, wherein said flowing of said sample past said ligand-receptor complex is carried out at a flow rate between 0.3 and 0.8 milliliters per minute.

20. A kit, comprising a lyophilized, dry reagent comprising: (a) a labeled ligand or labeled receptor bound to (b) a complementary receptor or a complementary ligand, wherein said complementary receptor or complementary ligand is immobilized on a solid supports, wherein said lyophilized, dry reagent is prepared by lyophilizing in the presence of a cryoprotectant.

21. The kit of claim 20, comprising a labelled antigen or labelled hapten bound to a complementary antibody, wherein said complementary antibody is immobilized on a solid support.

22. The kit of claim 20, wherein said complementary receptor or complementary ligand is capable of specific binding to an analyte selected from the group consisting of acetylcholine receptor antibody, adenovirus antigens, antibodies against adenovirus, aldosterone, acid phosphatase, alpha-1 fetoprotein, angiotensin converting enzyme, antiDNA antibody, antimitochondrial antibody, beta-2 microglobulin, creatine kinase isoenzymes, lactate dehydrogenase isoenzymes, complement components, chlamydia antigens, antibodies against chlamydia, cortisol, C-peptide, cyclic AMP, erthyropoietin, estradiol, ferritin, folic acid, follicle stimulating hormone, gastrin, glucagon, growth hormone, histocompatibility antigens, blood group antigens A and B, haptoglobin, antibodies against hepatitis A and B, hepatitis A and B antigens, antibodies against herpes, herpes antigens, human chorionic gonadotropin, HIV antigens, antibodies against HIV, antibodies against insulin, insulin, IgA, IgD, IgE, IgG, IgM, H. influenza antigen, antibodies against the H. influenza virus, intrinsic factor antibody, Borrelia burgdorferi antigens, antibodies against Borrelia burgdoferi, luteinizing hormone, metyrapone, myoglobin, neuron-specific-enolase, p24, pancreatic polypeptide, parathyroid hormone, placental lactogen, progesterone, prolactin, prostate specific antigen, rotavirus antigens, antibodies against rotavirus, antibodies against rubella, salmonella, serotonin, somatomedin-C, T.sub.3, T.sub.4, testosterone, thyroglobulin, thyroid stimulating hormone, thyroxine, thyroxine binding globulin, transferrin, tri-iodothyronine, vasoactive intestinal polypeptide, vitamins B.sub.6 and B.sub.12, staphylococcus antigens, antibodies against staphylococcus, enterotoxins, ricin, endotoxin, botulism toxin, venoms, amphetamine, methamphetamine, phenobarbital, cocaine, methadone, methaqualone, opiates (morphine, heroin), tetrahydrocannabinol (THC), phencyclidine (PCP), lysergic acid diethylamide (LSD), annabolic steroids, phenyl-butazone, amikacin, azidothymidine, benzodiazepines (diazepam and chlordiazepoxide), carbamazine, chloramphenicol, cyclosporine, digitoxin, digoxin, ethosuximide, gentamicin, imipramine, lidocaine, phenytoin, primidone, procainamide, propoxyphene, propranolol, quinidine, theophylline, tobramycin, valproic acid, trinitrotoluene, cyclonite, pentaerythritol tetranitrate, picric acid, nitroglycerin, herbicides, insecticides, polychlorinated biphenyls, polyaromatic hydrocarbons, heavy metals, glucose, F1 antigen of Y pestis, lethal factor or PA antigen from B. anthracis, and mycotoxins.

Details for Patent 5,354,654

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 01/15/1974 ⤷  Try a Trial 2039-02-26
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 12/27/1984 ⤷  Try a Trial 2039-02-26
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/15/1985 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.